26892-90-0Relevant academic research and scientific papers
Syntheses and photochromic behavior of biquinolinium salts
Nanasawa,Tomoda,Hirai
, p. 163 - 168 (2000)
Three isomers of N,N′-dibenzy-biquinolinium dibromide were synthesized and their photoinduced coloration properties were investigated in the thin poly(N-vinylpyrrolidone) films. Upon photo-irradiation, the colorless film of 4,4′-biquinolinium salt became
PANICINOTAM DERIVATIVE, PREPARATION METHOD AND USE THEREOF
-
Paragraph 0184; 0185, (2021/01/25)
Provided are penicinotam derivatives, a tautomer, a stereoisomer, a racemate, a nonequal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition comprising the deriva
Synthesis method and device of 4 -hydroxyquinoline -3 - formic acid
-
, (2021/09/21)
The invention relates to the technical field of medicine preparation, and particularly discloses a synthesis method and device of 4 -hydroxyquinoline -3 - formic acid, wherein o-nitrobenzoic acid and a monoethyl propionate potassium salt are condensed to obtain 3 - (2 - nitrophenyl) -3 - oxopropanoate. The ethyl powder is reacted with 3 - (2 - nitrophenyl) -3 - oxopropanoate to obtain 3 - (2 - aminophenyl) -3 - oxopropanoate. 3 - (2 - Aminophenyl) -3 - oxopropanoate was reacted with DMF-DMA and DMF via a closed loop to give 4 -hydroxyquinoline -3 - ethyl ester. The 4 -hydroxyquinoline -3 - formate was hydrolyzed under basic conditions to give 4 -hydroxyquinoline -3 - formic acid. 4 -hydroxyquinoline -3 - formic acid has the advantages of low cost, short reaction time and simple post-treatment in the synthesis process.
METHODS OF TREATMENT FOR CYSTIC FIBROSIS
-
, (2020/06/05)
This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
METHODS OF TREATMENT FOR CYSTIC FIBROSIS
-
, (2020/12/11)
This application describes methods of treating cystic fibrosis comprising administering Compound I:, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the foregoing.
COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS
-
, (2019/01/22)
Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.
METHODS OF TREATMENT FOR CYSTIC FIBROSIS
-
, (2019/02/06)
Methods of treating cystic fibrosis comprising administering at least Compound (I) of the formula. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound (I).
METHODS OF TREATMENT FOR CYSTIC FIBROSIS
-
, (2019/02/06)
Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.
CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
-
, (2019/05/07)
Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereofare disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
-
, (2019/06/23)
A single tablet comprising Compound I:. Methods of treating cystic fibrosis comprising administering one or more of such single tablets to a patient.
